MacroGenics Inc. (MGNX)
MGNX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1125345/000112534526000017/0001125345-26-000017-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | MGNX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2013 |
| SEC CIK | 0001125345 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $149.5M |
| Net income | -$74.6M |
| Operating income | -$72.8M |
| Net margin | -49.9% |
| Operating margin | -48.7% |
| Revenue growth | -0.3% |
| Cash | $57.2M |
| Total assets | $256.8M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.9× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-12 |
| Cash and burn | $49.0M cash; operating cash flow -$10.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 63,908,946 (2026-11-06); 63,258,532 a year earlier; 62,029,447 three years earlier. | Cover page 2026-11-06 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Tysons, Virginia, United States | PCAOB Form AP 2026-03-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $129K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $18.7M | -$20.1M | -$6.3M | $49.0M | No debt tags | $154.9M | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | $32.8M | $19.5M | -$40.7M | $113.9M | No debt tags | $189.2M | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | $20.8M | -$36.8M | -$35.8M | $66.5M | No debt tags | $163.2M | 10-Q 2026-05-13 |
| Q4 2025 2025-12-31 | $82.6M | -$14.2M | $43.0M | $57.2M | No debt tags | $155.6M | 10-K 2026-03-09 |
| Q3 2025 2025-09-30 | $53.0M | $16.8M | -$30.2M | $80.1M | No debt tags | $92.4M | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | $6.9M | -$36.3M | -$47.0M | $130.7M | No debt tags | $150.1M | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | $13.2M | -$41.0M | -$46.9M | $145.6M | No debt tags | $154.1M | 10-Q 2026-05-13 |
| Q4 2024 2024-12-31 | $19.4M | -$15.4M | -$38.4M | $182.8M | No debt tags | $150.0M | 10-K 2026-03-09 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2023-11-06 |
| Latest annual report | 10-K | 2026-03-09 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-13 |
| Latest proxy | DEFA14A | 2026-04-22 |
Source: SEC EDGAR submissions feed, 948 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -5.6% |
| 1 month | -35.7% |
| 3 months | -46.1% |
| Year to date | +36.6% |
| 1 year | +37.5% |
| From 52-week high | -54.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| RNA | Atrium Therapeutics Inc. | $6.43 | -14.38% | $138.7M |
| MSLE | Satellos Bioscience Inc. | $6.47 | -2.34% | $137.3M |
| SION | Sionna Therapeutics Inc. | $3.12 | -6.31% | $141.1M |
| MENS | Jyong Biotech Ltd. | $1.77 | +0.57% | $134.6M |
| NTHI | NeOnc Technologies Holdings Inc. | $4.54 | -7.54% | $131.0M |
| CNTN | Canton Strategic Holdings Inc. | $1.64 | -4.09% | $130.7M |
| VRXA | Veraxa Biotech AG | $1.04 | -5.86% | $147.8M |
| ABEO | Abeona Therapeutics Inc. | $2.60 | +7.44% | $148.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier